Conference Coverage

Revascularization in paraplegics best performed with PCI


 

AT THE 2018 CRT MEETING


When evaluated with propensity scoring, the differences in outcomes between those with or without paraplegia/quadriplegia were more modest, but MACE rates after CABG remained significantly higher (8.4% vs. 3.5%; P = .02). In contrast, the difference in MACE rates after propensity matching was no longer significantly higher in the paraplegia/quadriplegia group treated with PCI (4.4% vs. 2.0%; P = .46).

When CABG was compared to PCI among those with paraplegia/quadriplegia, the rate of in-hospital mortality was almost four times higher (9.5% vs. 2.5; P less than.01). Paraplegic/quadriplegic patients treated with CABG also had longer lengths of hospital stay and incurred higher treatment costs, according to Dr. Dai.

The moderator of the session at which these data were presented, Scott Schurmer, MD, chief of cardiology at Texas Tech Health Sciences Center, Lubbock, cautioned about the limitations of propensity scoring. He also suggested that PCI, based on concern for potential comorbidities in patients with paraplegia and quadriplegia, would likely be the choice of many physicians even without these data.

Dr. Dai reported no financial relationships to disclose.

SOURCE: Dai X. CRT 2018.

Pages

Recommended Reading

Targeting PCSK9 inhibitors to reap most benefit
MDedge Hematology and Oncology
Keep PCI patients on aspirin for noncardiac surgery
MDedge Hematology and Oncology
Prescribers mostly ignore clopidogrel pharmacogenomic profiling
MDedge Hematology and Oncology
New hematologic, cardiovascular system link may have therapeutic implications
MDedge Hematology and Oncology
DEFUSE 3: Thrombectomy time window broadens
MDedge Hematology and Oncology
VIDEO: COMPASS shows stroke-clot aspiration noninferior to retrieval
MDedge Hematology and Oncology
AHA: Heart health helps optimize breast cancer outcomes
MDedge Hematology and Oncology
VIDEO: Rivaroxaban plus aspirin halves ischemic strokes
MDedge Hematology and Oncology
Thrombectomy’s success treating strokes prompts rethinking of selection criteria
MDedge Hematology and Oncology
200 cardiovascular drugs now in development
MDedge Hematology and Oncology